Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Study acronym: HARMONi-7
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 274 → 285 locations
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Trial sites expanded: 270 → 274 locationsv10
  3. Trial sites expanded: 202 → 270 locationsv9
  4. Study sites: 120 to 202v8
  5. Study sites: 94 to 120v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 74 to 94v6
  2. Study sites: 45 to 74v5
  3. Study sites: 23 to 45v4
  4. Study sites: 3 to 23
    • Start date changed from estimate of Jan 2025 to Feb 27, 2025
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date: Dec 31, 2024 to Jan 2025
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Trial Details
NCT Number NCT06767514
Lead Sponsor Summit Therapeutics
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 780 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov